National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Infliximab (Remsima® subcutaneous). HTA ID: 20042

Infliximab (Remsima® subcutaneous) is indicated for treatment of adult patients with Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis in line with the adult indications of the IV formulation.

 

NCPE Assessment Process Complete
Rapid review commissioned 23/09/2020
Rapid review completed 15/10/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that Remsima SC not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.